[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604270":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":45,"collaborators":10,"id":49,"slug":10,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"The First Affiliated Hospital of University of South China","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"The serum AKR1B10 concentration was high in patients with cirrhosis.",null,[12],"Diagnostic Test: serum AKR1B10 levels",{"label":14,"type":10,"description":14,"interventionNames":15},"The serum AKR1B10 concentration was low in patients with cirrhosis",[12],[17],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"DIAGNOSTIC_TEST","serum AKR1B10 levels","Investigators collected blood from the patients every three months to test their serum AKR1B10 levels.",[9,14],[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Xi Zeng, PhD","CONTACT","17773486769","xzeng@usc.edu.cn",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"University of South China","RECRUITING","Hengyang","Hunan","421001","China","CN",{"type":38,"coordinates":39},"Point",[40,41],112.61888,26.88946,{"lat":41,"lon":40},[44],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhongtian Peng","Executive Director","100604270",false,"NCT07147335","The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients","The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients ------ Risk Early Warning and Follow-up Study","AKR1B10","Inclusion Criteria:\n\n* Meets diagnostic criteria for liver cirrhosis and chronic hepatitis\n* Aged 18-75 years, regardless of gender\n* Willing to participate in the study and provides signed informed consent\n* Has not participated in other clinical trials within the last 3 months\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Incomplete clinical data, serological or imaging records\n* Lost to follow-up prior to reaching the observational endpoints\n* Aged \\\u003C18 years or \\>75 years\n* Concurrent severe systemic diseases (e.g., involving cardiovascular, cerebral, pulmonary, renal, or hematopoietic systems)\n* Current or recent (within 3 months) participation in other clinical trials\n* Diagnosed with hepatocellular carcinoma (HCC)","ALL","18 Years","75 Years",{"count":60,"type":61},800,"ESTIMATED","3 Years","OBSERVATIONAL","Hepatocellular carcinoma (HCC) is a globally prevalent malignancy. In its characteristic \"chronic hepatitis-liver cirrhosis-HCC\" progression trilogy, patients with cirrhosis demonstrate a 5-year HCC incidence rate of 3%-5%, yet effective monitoring strategies remain lacking. Current early diagnosis relies on the combination of imaging techniques and serum alpha-fetoprotein (AFP), but AFP measurements are frequently confounded by pregnancy and liver diseases, resulting in suboptimal sensitivity and specificity. In recent years, novel tumor biomarkers such as AKR1B10 (Aldo-keto reductase family 1 member B10) have been examined. This multicenter prospective cohort study aims to validate the predictive value of serum AKR1B10 for malignant transformation in cirrhosis-HCC progression, and evaluate its combined efficacy with existing risk prediction models, ultimately establishing a high-sensitivity early diagnostic strategy for clinical implementation.",[66,67],"Cirrhosis","Hepotacellular Carcinoma",[54,69,70],"Hepotacellular carcinoma","cirrhosis","2025-08-28",{"date":73,"type":74},"2025-08-29","ACTUAL",{"date":76,"type":74},"2025-05-16",{"date":78,"type":61},"2028-03-31",{"name":5,"class":6},1]